PathoGenesis Tobi Use Per Patient Can Be Raised About 50%, CEO Says
Executive Summary
PathoGenesis believes that per patient use of Tobi inhaled tobramycin can be increased by about 50%.
You may also be interested in...
Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues
Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.
Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues
Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.
Sankyo Parke Davis Will Double Sales Force To Market GelTex Cholestagel
Sankyo Parke Davis intends to double its sales force to support the marketing and sales of GelTex' cholesterol reduction agent Cholestagel (colesevelam).